Business Description

Description
Dendreon Corp is a Delaware corporation. The Company is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE(r) (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The Other potential product candidates we have under development include our investigational active cellular immunotherapy, DN24-02, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu. In addition, the Company has developed an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company's competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration ('OSHA'), and the Environmental Protection Agency ('EPA'), and to regulation under the Toxic Substances Control Act.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset -0.19
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -9.17
Distress
Grey
Safe
Beneish M-Score -4.45
Manipulator
Not Manipulator

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.81
Quick Ratio 2.79
Days Inventory 193.46
Days Sales Outstanding 33.5
Days Payable 6.18

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.5

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 50.92
Operating Margin % -15.06
Net Margin % -35.72
FCF Margin % -56
ROA % -19.54
ROIC % -146.45
ROC (Joel Greenblatt) % -24.33

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 0.02
EV-to-Revenue 1.61
Earnings Yield (Greenblatt) % -22.5

Financials

FRA:DNR's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Dendreon Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 117.459
EPS (TTM) (€) -0.183
Beta 0
Volatility % 0
14-Day RSI 0
14-Day ATR (€) 0
20-Day SMA (€) 0
12-1 Month Momentum % 0
52-Week Range (€) 0.08 - 2.54
Shares Outstanding (Mil) 160.31

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Dendreon Corp Filings

Filing Date Document Date Form
No Filing Data

Dendreon Corp Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Dendreon Corp Frequently Asked Questions

What is Dendreon Corp(FRA:DNR)'s stock price today?
The current price of FRA:DNR is €0.13. The 52 week high of FRA:DNR is €2.54 and 52 week low is €0.08.
When is next earnings date of Dendreon Corp(FRA:DNR)?
The next earnings date of Dendreon Corp(FRA:DNR) is .
Does Dendreon Corp(FRA:DNR) pay dividends? If so, how much?
Dendreon Corp(FRA:DNR) does not pay dividend.

Press Release

Subject Date
No Press Release